VPRIV CLINICAL PROGRAM OVERVIEW

VPRIV was evaluated in 99 patients (aged ≥ 4 years) across three initial clinical trials. Some of these patients were then enrolled into one phase III, open-label, long-term extension trial conducted in adult and pediatric patients (n=93; patients aged ≥ 4 years).¹

Click  through the sections below to learn more about VPRIV’s clinical trials.

Treatment-naïve: patients who had not received disease-specific treatment within the 30 months prior to starting VPRIV.⁶

Treatment-experienced: patients previously treated with imiglucerase for a minimum of 30 consecutive months prior to switching to VPRIV.⁵